Pharma

johnson-johnson-launched-11-new-products-since-2009-which-have-raked-in-17-percent-of-its-total-pharma-sales-last-year

J&J to seek nod for 11 new drugs by 2017

  • US
  • |
  • News

Singapore: Johnson & Johnson (J&J) revealed that it is aiming to apply for approval of 10 new drugs in the US and Europe, a polio vaccine for other parts of the world and 25 variations of its existing drugs by 2017. Dr Joaquin Duato,... Read more

one-third-of-ranbaxy-s-14-600-global-sales-staff-may-lose-their-jobs

Ranbaxy may fire 1/3rd of its global sales staff


  • US
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Ranbaxy Laboratories is contemplating on slashing its global sales staff by about a third, with a majority of... Read more

daiichi-may-take-legal-action-against-former-shareholders-of-ranbaxy-as-it-believes-that-they-concealed-and-misrepresented-critical-information-concerning-the-us-department-of-justice-doj-and-us-fda-inves

Daiichi may take legal action against ex-Ranbaxy promoters...


  • Japan
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Breaking its silence for the first time in 10 days after Indian drug major Ranbaxy's $500 million settlement of... Read more

south-korea-s-biotechnology-is-strengthening-its-r-d-capacity-in-genomics-proteomics-and-bioinformatics

South Korea: Strengthens position using clinical research

  • Korea
  • |
  • Analysis
  • |
  • By Saptarshi Chaudhuri
  • |
  • 1 Comment

The year 2012 has been particularly eventful for South Korea. Not only has the nation elected its first woman president, Ms Park Geun-hye,... Read more

singapore-continues-to-enhance-its-biomedical-sciences-cluster

Singapore: Rides the medtech wave

  • Singapore
  • |
  • Analysis
  • |
  • By Amrita Tejasvi
  • |
  • 1 Comment

With an aim to become the number 1 hotspot for global bioscience industry in Asia, Singapore has committed $13.05 billion (S$16.1 billion)... Read more

ranbaxy-has-been-hit-hard-by-the-gavel

Ranbaxy pleads guilty, will pay $500 mn to the US

  • US
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

New Delhi: Ranbaxy Laboratories has reached a final settlement agreement regarding a previously disclosed investigation by the US Department... Read more

malaysia-is-emerging-as-a-bioscience-hub-for-international-life-science-companies-by-providing-them-smooth-passage-to-set-up-manufacturing-plants

Malaysia: Emerges as a manufacturing hub

  • Malaysia
  • |
  • Analysis
  • |
  • By Amrita Tejasvi
  • |
  • 0 Comment

Malaysia is now emerging as a manufacturing hub for international pharmaceutical companies and provides them smooth passage to set up manufacturing... Read more

indian-life-science-is-leveraging-on-increasing-sales-of-generic-medicines-continued-growth-in-chronic-therapies-and-greater-penetration-in-rural-markets

India: Policy reforms enables bioscience sector

  • India
  • |
  • Analysis
  • |
  • By Amrita Tejasvi
  • |
  • 0 Comment

Leveraging on the back of increasing sales of generic medicines, continued growth in chronic therapies and a greater penetration in rural... Read more

in-late-2012-the-national-development-and-reform-commission-ndrc-of-china-announced-a-new-price-cut-policy-for-pharmaceuticals-effective-from-february-1-2013

China: Shines despite slower pace of growth

  • China
  • |
  • Analysis
  • |
  • By Saptarshi Chaudhuri
  • |
  • 0 Comment

The investments pouring in China are aligned with the government's plan to boost the pharmaceutical industry of the country in its 12th... Read more

the-australian-government-is-under-pressure-to-offer-drugs-at-affordable-prices-and-to-lower-cost-of-healthcare

Australia: Controls healthcare cost, drives market

  • Australia
  • |
  • Analysis
  • |
  • By Amrita Tejasvi
  • |
  • 0 Comment

Increase in aging population along with rising burden of non communicable diseases in Australia have been putting pressure on the government... Read more

nymalize-nimodipine-was-previously-granted-orphan-designation-which-provides-seven-years-of-market-exclusivity

Arbor gets FDA approval for its first NDA

  • US
  • |
  • Regulatory
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: The US Food and Drug Administration (FDA) has approved Arbor Pharmaceutical's New Drug Application (NDA) for Nymalize (nimodipine)... Read more

farewell-ms-anna-protopapas-executive-vp-of-bd-takeda-will-replace-millennium-pharma-s-outgoing-ceo-ms-deborah-dunsire

CEO of Takeda's Millennium Pharma quits abruptly

  • Japan
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Ms Deborah Dunsire, CEO, Millennium Pharmaceuticals, is leaving the company in an abrupt departure. Ms Dunsire fueled the emergence... Read more

Special Features

Survey Box

Chinese Bird Flu H7N9

Have Chinese scientists done the right thing by fusing human and avian flu strains to create new killer viruses?

Send this article by email

X